What was the market valuation of the US bone pain-treatment market in 2024?

The market valuation was $1490.0 Million in 2024. Read More

What is the projected market valuation for the US bone pain-treatment market by 2035?

The projected valuation for 2035 is $3000.0 Million. Read More

What is the expected CAGR for the US bone pain-treatment market during the forecast period 2025 - 2035?

The expected CAGR during this period is 6.57%. Read More

Which companies are considered key players in the US bone pain-treatment market?

Key players include Pfizer Inc, Johnson & Johnson, Bristol-Myers Squibb, AbbVie Inc, Amgen Inc, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, and Sanofi S.A. Read More

What are the main types of drugs used in the US bone pain-treatment market?

Main types of drugs include Ibuprofen, Acetaminophen, Paracetamol, and Morphine. Read More

What were the revenue figures for Ibuprofen in the US bone pain-treatment market?

Revenue figures for Ibuprofen ranged from $200.0 Million to $400.0 Million. Read More

How does the revenue for Morphine compare to other drugs in the market?

Morphine generated revenue between $740.0 Million and $1500.0 Million, indicating a strong market presence. Read More

What types of antibiotics are relevant in the US bone pain-treatment market?

Relevant antibiotics include Ciprofloxacin, Clindamycin, and Vancomycin. Read More

What were the revenue figures for Vancomycin in the US bone pain-treatment market?

Vancomycin's revenue ranged from $990.0 Million to $2000.0 Million. Read More

How does the market for Acetaminophen compare to that of Paracetamol?

Acetaminophen's revenue ranged from $300.0 Million to $600.0 Million, while Paracetamol's ranged from $250.0 Million to $500.0 Million. Read More

US Bone Pain Treatment Market

US Bone Pain Treatment Market Research Report By Type (Ibuprofen (Advil), Acetaminophen (Tylenol), Paracetamol, Morphine), By Antibiotics (Ciprofloxacin, Clindamycin, Vancomycin), By Growth Factors (Growing elderly population, Prevalence of chronic disorders like cancer, Diabetic neuropathy, Osteoarthritis, Technological improvements) and By Restraints (Drug exploitation, Expiration of patents on prescription pain medications, Availability of pain relief devices) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.57%

2024 Market Size

$ 1,490 Million

2035 Market Size

$ 3,000 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/18340-HCR | Pages: 100 | Author: Nidhi Mandole, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type of Drug (USD Million)
  1. 4.1.1 Ibuprofen (Advil)
  2. 4.1.2 Acetaminophen (Tylenol)
  3. 4.1.3 Paracetamol
  4. 4.1.4 Morphine
2. 4.2 Chemicals and Materials, BY Type of Antibiotics (USD Million)
  1. 4.2.1 Ciprofloxacin
  2. 4.2.2 Clindamycin
  3. 4.2.3 Vancomycin
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AbbVie Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis AG (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche Holding AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GlaxoSmithKline plc (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi S.A. (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE OF DRUG
3. 6.3 US MARKET ANALYSIS BY TYPE OF ANTIBIOTICS
4. 6.4 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF CHEMICALS AND MATERIALS
7. 6.7 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
8. 6.8 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
10. 6.10 CHEMICALS AND MATERIALS, BY TYPE OF DRUG, 2024 (% SHARE)
11. 6.11 CHEMICALS AND MATERIALS, BY TYPE OF DRUG, 2024 TO 2035 (USD Million)
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE OF ANTIBIOTICS, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TYPE OF ANTIBIOTICS, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF DRUG, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE OF ANTIBIOTICS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Bone Pain Treatment Market Segmentation

US Bone Pain Treatment Market By Type of Drug (USD Million, 2025-2035)

Ibuprofen (Advil)
Acetaminophen (Tylenol)
Paracetamol
Morphine

US Bone Pain Treatment Market By Type of Antibiotics (USD Million, 2025-2035)

Ciprofloxacin
Clindamycin
Vancomycin

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”